---

---

tags : Drug    crawled date : 2021 - 11 - 29   

save search

---

Certara Announces Update of D360™ Scientific Informatics SoftwareNew capabilities increase efficiency in analyzing and developing small molecules and biologic drugs
Published: 2021-11-29 (Crawled : 23:00) - biospace.com/
CERT | $16.19 -4.48% -4.69% 490K |

| -38.82% | O: 0.47% H: 1.86% C: 0.71%
software drug

---

Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast CancerPNV2 demonstrates reduction of metastases in animal model
Published: 2021-11-29 (Crawled : 15:00) - biospace.com/
ADIL | $2.17 -6.47% -6.91% 150K |

Health Technology

| -23.86% | O: -0.35% H: 1.76% C: -9.86%
drug pre-clinical positive cancer negative breast cancer preclinical

---

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
CELU | News F | $3.17 -4.23% -4.42% 42K |

| -52.15% | O: 1.48% H: 2.19% C: -2.19%
new drug fda clearance application drug fda clearance positive therapy cancer her2- her2

---

Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Published: 2021-11-29 (Crawled : 14:00) - biospace.com/
VIRX | $0.8971 -4.18% -4.36% 79K |

Manufacturing

| -81.35% | O: 3.57% H: 4.21% C: -12.45%
treatment fda drug granted therapeutics orphan drug positive t-cell designation

---

G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M |

Health Technology

| -4.44% | O: 0.74% H: 0.0% C: 0.0%
GTHX | $4.16 -2.8% -2.88% 690K |

Health Technology

| -68.6% | O: 0.75% H: 0.82% C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics

---

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Published: 2021-11-29 (Crawled : 13:00) - globenewswire.com
VRCA | $6.91 -2.13% -2.17% 200K |

Health Technology

| -36.91% | O: -5.72% H: 5.02% C: -0.09%
molluscum new drug treatment application drug submission resubmission

---

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
IMNM | $17.175 -1.18% -1.19% 850K |

Health Technology

| 9.22% | O: 7.88% H: 13.26% C: 12.55%
covid new drug treatment application drug submission

---

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -14.13% | O: -0.24% H: 0.0% C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| 29.3% | O: -1.18% H: 1.16% C: 0.49%
psoriasis food treatment europe application drug plague

---

G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M |

Health Technology

| -4.44% | O: 0.74% H: 0.0% C: 0.0%
GTHX | $4.16 -2.8% -2.88% 690K |

Health Technology

| -68.6% | O: 0.75% H: 0.82% C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics

---

Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
Published: 2021-11-29 (Crawled : 12:00) - biospace.com/
FENC M | $10.5 -3.05% -3.14% 100K |

Health Technology

| 9.5% | O: -50.05% H: 0.0% C: 0.0%
new drug fda solid tumors application drug

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---